$AMRN
AMARIN CORP PLC\UK Stock $amrn

$amrn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000095017022002401 Filed on March 01, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$144.5M	$583.2M	$167.3M
YoY Change	-13.61%	-5.03%	16.73%
Cost Of Revenue	$30.64M	$121.3M	$34.77M
YoY Change	-11.89%	-7.7%	13.38%
Gross Profit	$113.9M	$461.9M	$132.5M
YoY Change	-14.06%	-4.3%	17.65%
Gross Profit Margin	78.8%	79.2%	79.21%
Selling, General & Admin	$92.37M	$408.3M	$116.8M
YoY Change	-20.93%	-11.87%	21.65%
% of Gross Profit	81.13%	88.41%	88.17%
Research & Development	$5.753M	$29.31M	$8.509M
YoY Change	-32.39%	-24.77%	-23.32%
% of Gross Profit	5.05%	6.35%	6.42%
Depreciation & Amortization	$781.0K	$600.0K	$511.0K
YoY Change	52.84%	0.0%	58.7%
% of Gross Profit	0.69%	0.13%	0.39%
Operating Expenses	$98.12M	$451.4M	$125.3M
YoY Change	-21.71%	-10.14%	16.99%
Operating Profit	$15.74M	$10.50M	$7.158M
YoY Change	119.82%	-153.43%	30.38%
Interest Expense	$172.0K	$129.0K	$388.0K
YoY Change	-55.67%	-95.05%	-76.27%
% of Operating Profit	1.09%	1.23%	5.42%
Other Income/Expense, Net	$88.00K	-$302.0K	$54.00K
YoY Change	62.96%	-390.38%	-49.53%
Pretax Income	$16.39M	$11.29M	$7.600M
YoY Change	115.7%	-165.44%	5.09%
Income Tax	$1.695M	$3.562M	$2.674M
% Of Pretax Income	10.34%	31.55%	35.18%
Net Earnings	$14.70M	$7.729M	$4.926M
YoY Change	198.38%	-142.94%	-30.31%
Net Earnings / Revenue	10.17%	1.33%	2.95%
Basic Earnings Per Share		$0.02
Diluted Earnings Per Share	$34.76K	$0.02	$12.61K
COMMON SHARES
Basic Shares Outstanding		396.0M
Diluted Shares Outstanding		402.5M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$454.1M	$454.1M	$500.9M
YoY Change	-9.34%	-9.34%	-22.29%
Cash & Equivalents	$219.5M	$219.5M	$187.0M
Short-Term Investments	$234.7M	$234.7M	$314.0M
Other Short-Term Assets	$26.27M	$26.27M	$34.86M
YoY Change	-24.65%	-24.51%	102.47%
Inventory	$234.7M	$234.7M	$188.9M
Prepaid Expenses
Receivables	$163.7M	$163.7M	$154.6M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$878.7M	$878.7M	$879.2M
YoY Change	-0.06%	-0.05%	2.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.425M	$9.085M	$2.016M
YoY Change	-29.32%	-10.05%	-14.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$35.00M	$35.00M	$62.47M
YoY Change	-43.98%	-44.01%
Other Assets	$456.0K	$121.7M	$432.0K
YoY Change	5.56%	30327.5%	-59.78%
Total Long-Term Assets	$189.3M	$189.3M	$86.79M
YoY Change	118.16%	118.13%	219.03%
TOTAL ASSETS
Total Short-Term Assets	$878.7M	$878.7M	$879.2M
Total Long-Term Assets	$189.3M	$189.3M	$86.79M
Total Assets	$1.068B	$1.068B	$966.0M
YoY Change	10.56%	10.57%	9.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$114.9M	$114.9M	$105.9M
YoY Change	8.54%	8.52%	111.96%
Accrued Expenses	$253.1M	$207.5M	$198.6M
YoY Change	27.42%	22.14%	42.06%
Deferred Revenue	$2.649M		$2.926M
YoY Change	-9.47%		24.94%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$370.7M	$370.7M	$307.4M
YoY Change	20.57%	20.59%	26.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.648M	$30.28M	$6.214M
YoY Change	23.08%	-2.62%	65.66%
Total Long-Term Liabilities	$7.648M	$30.28M	$6.214M
YoY Change	23.08%	-2.62%	65.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$370.7M	$370.7M	$307.4M
Total Long-Term Liabilities	$7.648M	$30.28M	$6.214M
Total Liabilities	$401.0M	$401.0M	$338.5M
YoY Change	18.45%	18.45%	23.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.421B		-$1.429B
YoY Change	-0.54%		1.28%
Common Stock	$294.0M		$290.1M
YoY Change	1.35%		7.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$60.73M		$51.08M
YoY Change	18.88%		42.29%
Treasury Stock Shares	$7.487M		$5.887M
Shareholders Equity	$667.1M	$667.1M	$627.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.068B	$1.068B	$966.0M
YoY Change	10.56%	10.57%	9.5%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$14.70M	$7.729M	$4.926M
YoY Change	198.38%	-142.94%	-30.31%
Depreciation, Depletion And Amortization	$781.0K	$600.0K	$511.0K
YoY Change	52.84%	0.0%	58.7%
Cash From Operating Activities	-$28.24M	-$66.54M	-$38.32M
YoY Change	-26.31%	205.97%	328.86%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$25.02M	$104.1M	$23.69M
YoY Change	5.62%	-127.63%
Cash From Investing Activities	$25.02M	$104.1M	$23.69M
YoY Change	5.62%	-127.62%	-6607.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-196.0K	-5.073M	-5.606M
YoY Change	-96.5%	-91.39%	-70.98%
NET CHANGE
Cash From Operating Activities	-28.24M	-66.54M	-38.32M
Cash From Investing Activities	25.02M	104.1M	23.69M
Cash From Financing Activities	-196.0K	-5.073M	-5.606M
Net Change In Cash	-3.420M	32.49M	-20.24M
YoY Change	-83.11%	-107.1%	-29.26%
FREE CASH FLOW
Cash From Operating Activities	-$28.24M	-$66.54M	-$38.32M
Capital Expenditures			$0.00
Free Cash Flow			-$38.32M
YoY Change			347.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2021	dei	Entity Registrant Name EntityRegistrantName	AMARIN CORP PLC\UK
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000897448
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent
CY2021	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	0-21392
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	77 Sir John Rogerson’s Quay
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Block C
CY2021	dei	Entity Address Address Line3 EntityAddressAddressLine3	Grand Canal Docklands
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2
CY2021	dei	Entity Address Country EntityAddressCountry	IE
CY2021	dei	City Area Code CityAreaCode	353 (0) 1
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Local Phone Number LocalPhoneNumber	6699 020
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Security12b Title Security12bTitle	American Depositary Shares (ADS(s)), each ADSrepresenting the right to receive one (1) Ordinary Share ofAmarin Corporation plc
CY2021	dei	Trading Symbol TradingSymbol	AMRN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1710300000
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219454000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	186964000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3918000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3915000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	234674000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	313969000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	163653000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	154574000
CY2021Q4	us-gaap	Inventory Net InventoryNet	234676000
CY2020Q4	us-gaap	Inventory Net InventoryNet	188864000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22352000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	30947000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	878727000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	879233000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2016000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	34996000
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	62469000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	121254000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7660000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8054000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	456000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	432000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23547000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13817000
CY2021Q4	us-gaap	Assets Assets	1068065000
CY2020Q4	us-gaap	Assets Assets	966021000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	114922000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	105876000
CY2021Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	253111000
CY2020Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	198641000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2649000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2926000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	370682000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	307443000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	14060000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15706000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8576000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9153000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7648000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6214000
CY2021Q4	us-gaap	Liabilities Liabilities	400966000
CY2020Q4	us-gaap	Liabilities Liabilities	338516000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	404084775
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	396598008
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	398425000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	392538081
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	294027000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	290115000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1855246000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1817649000
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7486767
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5886919
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	60726000
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	51082000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1421448000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1429177000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	667099000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627505000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1068065000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	966021000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	583187000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	614060000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	429755000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	121327000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	131444000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	96019000
CY2021	us-gaap	Gross Profit GrossProfit	461860000
CY2020	us-gaap	Gross Profit GrossProfit	482616000
CY2019	us-gaap	Gross Profit GrossProfit	333736000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	408334000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	463312000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	323623000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29307000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38959000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34392000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	13717000
CY2021	us-gaap	Operating Expenses OperatingExpenses	451358000
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	608263000
CY2020	us-gaap	Operating Expenses OperatingExpenses	502271000
CY2019	us-gaap	Operating Expenses OperatingExpenses	358015000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	10502000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-19655000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-24279000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1220000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	4901000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	8499000
CY2021	us-gaap	Interest Expense InterestExpense	129000
CY2020	us-gaap	Interest Expense InterestExpense	2605000
CY2019	us-gaap	Interest Expense InterestExpense	6626000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-302000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	104000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11291000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17255000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22481000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3562000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	745000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	164000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7729000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-18000000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-22645000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	395992000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	381759000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	342538000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	402480000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	381759000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	342538000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	152330000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	440108000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2165000
CY2019	amrn	Stock Issued During Period Value Milestone Payment StockIssuedDuringPeriodValueMilestonePayment	6216000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24478000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-25487000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31098000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-22645000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-504000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1957000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-18000000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10366000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	24000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5158000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-15182000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45813000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627505000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1650000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2921000
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-9644000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36938000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	7729000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	667099000
CY2021	us-gaap	Profit Loss ProfitLoss	7729000
CY2020	us-gaap	Profit Loss ProfitLoss	-18000000
CY2019	us-gaap	Profit Loss ProfitLoss	-22645000
CY2021	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	587000
CY2020	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	597000
CY2019	amrn	Depreciation And Amortization Excluding Amortization Of Intangible Assets DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets	180000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1929000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1602000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36938000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	45813000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	30917000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	635000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1644000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2270000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1441000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	679000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9079000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38144000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	49907000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	167066000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	112095000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18967000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8595000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17636000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-642000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	900000
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-738000
CY2020	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	1329000
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-428000
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-210000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1923000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2214000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	136000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	51516000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	114741000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	65913000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1253000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2629000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-5840000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66537000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21746000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9366000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	394294000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	301989000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	290195000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	678700000
CY2021	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	4000
CY2020	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	-252000
CY2019	amrn	Disposal Purchase Of Furniture Fixtures And Equipment DisposalPurchaseOfFurnitureFixturesAndEquipment	-2478000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	104103000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-376963000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2478000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	440108000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1650000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1957000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2165000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2921000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5158000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24478000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	504000
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	50336000
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	31652000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9644000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	15182000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25487000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5073000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-58907000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	409612000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	32493000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-457616000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	397768000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	190879000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	648495000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	250727000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	223372000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	190879000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	648495000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	2043000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	4591000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3656000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-207000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-67000
CY2021	amrn	Non Cash Or Part Non Cash Milestone Payment NonCashOrPartNonCashMilestonePayment	12000000
CY2019	amrn	Non Cash Or Part Non Cash Milestone Payment NonCashOrPartNonCashMilestonePayment	8457000
CY2019	amrn	Initial Recognition Of Operating Lease Right Of Use Asset InitialRecognitionOfOperatingLeaseRightOfUseAsset	8995000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	18020000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Assets Assets	1068100000
CY2021Q4	amrn	Cash And Liquid Short Term And Long Term Investments CashAndLiquidShortTermAndLongTermInvestments	489100000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	878700000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	219500000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	234700000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	163700000
CY2021Q4	us-gaap	Inventory Net InventoryNet	234700000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	35000000.0
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	121300000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	0
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Estimates are used in determining such items as provisions for sales returns, rebates and incentives, chargebacks, and other sales allowances; depreciable/amortizable lives; asset impairments; valuation allowance on deferred taxes; probabilities of achievement of performance conditions for certain equity awards; amounts recorded for licensing revenue; contingencies and accruals. Because of the uncertainties inherent in such estimates, actual results may differ from these estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
CY2021	amrn	Accounts Receivable Credit Period AccountsReceivableCreditPeriod	P30D
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	262948000
CY2020Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	203875000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	163653000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	154574000
CY2021	amrn	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	7729000
CY2020	amrn	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-18000000
CY2019	amrn	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-22645000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	395992000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	381759000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	342538000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	402480000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	381759000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	342538000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents, short-term and long-term investments, and accounts receivable. The Company maintains substantially all of its cash and cash equivalents and short-term and long-term investments, in financial institutions believed to be of high-credit quality.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A significant portion of the Company’s sales are to wholesalers in the pharmaceutical industry. The Company monitors the creditworthiness of customers to whom it grants credit terms and has not experienced any credit losses. The Company does not require collateral or any other security to support credit sales. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers individually accounted for 10% or more of the Company’s gross product sales. Customers A, B, and C accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, of gross product sales for the year ended December 31, 2021 and represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, of the gross accounts receivable balance as of December 31, 2021. Customers A, B, and C accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, of gross product sales for the year ended December 31, 2020 and represented </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, of the gross accounts receivable balance as of December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has not experienced any significant write-offs of its accounts receivable. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected; however, the Company is monitoring the potential negative impact of COVID-19 on the Company’s customers’ ability to meet their financial obligations.</span></p>
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-600000
CY2021	us-gaap	Debt Instrument Term DebtInstrumentTerm	P24M
CY2021Q4	amrn	Held To Maturity Securities Continuous Unrealized Gain Loss Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedGainLossPositionFairValue	200000
CY2020Q4	amrn	Held To Maturity Securities Continuous Unrealized Gain Loss Position Fair Value HeldToMaturitySecuritiesContinuousUnrealizedGainLossPositionFairValue	-500000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	amrn	Number Of Sales Representatives NumberOfSalesRepresentatives	300
CY2021	amrn	Restructuring Costs Incurred RestructuringCostsIncurred	14115000
CY2021	us-gaap	Payments For Restructuring PaymentsForRestructuring	12225000
CY2021	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-398000
CY2021	us-gaap	Restructuring Reserve Translation And Other Adjustment RestructuringReserveTranslationAndOtherAdjustment	-306000
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	1186000
CY2021	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9Y3M18D
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32081000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20081000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8534000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6264000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23547000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13817000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2300000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2546000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2546000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2546000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2546000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2546000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10817000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	23547000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	107695000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	50657000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	41965000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	30388000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	206270000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	107819000
CY2021Q4	amrn	Inventory Current And Non Current InventoryCurrentAndNonCurrent	355930000
CY2020Q4	amrn	Inventory Current And Non Current InventoryCurrentAndNonCurrent	188864000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	121300000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3346000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3632000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1921000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1616000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2016000
CY2021	us-gaap	Depreciation Depreciation	600000
CY2020	us-gaap	Depreciation Depreciation	600000
CY2019	us-gaap	Depreciation Depreciation	200000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19730000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22772000
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3563000
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	6220000
CY2021Q4	amrn	Accrued Liabilities Sales Allowances Current AccruedLiabilitiesSalesAllowancesCurrent	184216000
CY2020Q4	amrn	Accrued Liabilities Sales Allowances Current AccruedLiabilitiesSalesAllowancesCurrent	140863000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	45602000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	28786000
CY2021Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	253111000
CY2020Q4	amrn	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	198641000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	196100000
CY2021Q4	amrn	Communication Costs Pertaining To Marketing Commitments CommunicationCostsPertainingToMarketingCommitments	300000
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.05
CY2015Q1	amrn	Equity Offering Costs EquityOfferingCosts	700000
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1203845
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1623460
CY2021	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	2921000
CY2020	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	5158000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7900000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5600000
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	900000
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24034000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26743000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6815000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	16000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2428000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	295000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2248000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	5391000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	238000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	254000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	19633000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	22040000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24034000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26743000
CY2021Q4	amrn	Deferred Tax Liabilities Subject To Expiration DeferredTaxLiabilitiesSubjectToExpiration	0
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	10222000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	14915000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	10269000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11291000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17255000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22481000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2690000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	45000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	716000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	700000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	164000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	156000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3562000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	745000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	164000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5222000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1972000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1777000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3057000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1956000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-914000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1619000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-26793000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	1278000
CY2021	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	-546000
CY2020	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	22865000
CY2019	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	-2141000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3562000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	745000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	164000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2823000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4314000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5620000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-4416000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	128000
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3009000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-546000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	22865000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2141000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	5249000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	6122000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	5472000
CY2021	amrn	Income Tax Reconciliation Windfall Tax Benefit Shortfall IncomeTaxReconciliationWindfallTaxBenefitShortfall	-81000
CY2020	amrn	Income Tax Reconciliation Windfall Tax Benefit Shortfall IncomeTaxReconciliationWindfallTaxBenefitShortfall	3262000
CY2019	amrn	Income Tax Reconciliation Windfall Tax Benefit Shortfall IncomeTaxReconciliationWindfallTaxBenefitShortfall	14342000
CY2021	amrn	Income Tax Reconciliation Disqualifying Disposition Windfall IncomeTaxReconciliationDisqualifyingDispositionWindfall	219000
CY2020	amrn	Income Tax Reconciliation Disqualifying Disposition Windfall IncomeTaxReconciliationDisqualifyingDispositionWindfall	253000
CY2019	amrn	Income Tax Reconciliation Disqualifying Disposition Windfall IncomeTaxReconciliationDisqualifyingDispositionWindfall	2849000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1170000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	6225000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1607000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-8372000
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-138000
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-3222000
CY2020	amrn	Income Tax Reconciliation Net Operating Loss Carryback IncomeTaxReconciliationNetOperatingLossCarryback	2465000
CY2021	amrn	Income Tax Rate Reconciliation Cumulative Translation Adjustment Amount IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount	4109000
CY2020	amrn	Income Tax Rate Reconciliation Cumulative Translation Adjustment Amount IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount	-10852000
CY2019	amrn	Income Tax Rate Reconciliation Cumulative Translation Adjustment Amount IncomeTaxRateReconciliationCumulativeTranslationAdjustmentAmount	2025000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	863000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4283000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-443000
CY2021	amrn	Income Tax Reconciliation Tax Reserve IncomeTaxReconciliationTaxReserve	5160000
CY2020	amrn	Income Tax Reconciliation Tax Reserve IncomeTaxReconciliationTaxReserve	3422000
CY2019	amrn	Income Tax Reconciliation Tax Reserve IncomeTaxReconciliationTaxReserve	18799000
CY2019	amrn	Income Tax Reconciliation Liquidation IncomeTaxReconciliationLiquidation	1727000
CY2019	amrn	Income Tax Reconciliation Long Term Debt Royalty Bearing Instrument IncomeTaxReconciliationLongTermDebtRoyaltyBearingInstrument	-644000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3562000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	745000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	164000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	127378000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	125859000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.12
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5054000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4194000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8563000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7565000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	15803000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	14690000
CY2021Q4	amrn	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	2348000
CY2020Q4	amrn	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	2219000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	11257000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	14702000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165349000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	165035000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160295000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160841000
CY2021Q4	amrn	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	3404000
CY2020Q4	amrn	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	2399000
CY2021Q4	amrn	Deferred Tax Liability Lease Asset DeferredTaxLiabilityLeaseAsset	1639000
CY2020Q4	amrn	Deferred Tax Liability Lease Asset DeferredTaxLiabilityLeaseAsset	1784000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	11000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	11000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5054000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4194000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160841000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137976000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2899000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12453000
CY2021	amrn	Valuation Allowances And Reserves Foreign Currency Translation ValuationAllowancesAndReservesForeignCurrencyTranslation	-3445000
CY2020	amrn	Valuation Allowances And Reserves Foreign Currency Translation ValuationAllowancesAndReservesForeignCurrencyTranslation	10412000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160295000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160841000
CY2021Q4	amrn	Deferred Tax Assets Operating Loss Carryforwards Change In Amount DeferredTaxAssetsOperatingLossCarryforwardsChangeInAmount	-50600000
CY2021Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2021Q4	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16664000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4813000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1481000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.88
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	299000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	12.04
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1204000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.43
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18493000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.32
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7762000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12487000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.81
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7744000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	18193000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.30
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7761000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	13229000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.12
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.43
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.07
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	21100000
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	22500000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14500000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2900000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5200000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	24500000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4900000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9000000.0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	90500000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	30700000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	23000000.0
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	22400000
CY2019	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	16300000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0053
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0136
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0033
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0174
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0155
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0295
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.96
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.99
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.84
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.99
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.92
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.94
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	13900000
CY2020	us-gaap	Restricted Stock Expense RestrictedStockExpense	23400000
CY2019	us-gaap	Restricted Stock Expense RestrictedStockExpense	14600000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	36938000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	45813000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	30917000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1900000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1700000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1100000
CY2019Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	128557000
CY2020	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	822813000
CY2020	amrn	Provision Related To Prior Period Sales ProvisionRelatedToPriorPeriodSales	3872000
CY2020	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	637999000
CY2020	amrn	Credits Payments Made For Prior Period Sales CreditsPaymentsMadeForPriorPeriodSales	118675000
CY2020Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	190824000
CY2021	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	852420000
CY2021	amrn	Provision Related To Prior Period Sales ProvisionRelatedToPriorPeriodSales	2034000
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	583437000
CY2021	amrn	Credits Payments Made For Prior Period Sales CreditsPaymentsMadeForPriorPeriodSales	175547000
CY2021Q4	amrn	Valuation Allowances Provisions And Reserves Balance Net ValuationAllowancesProvisionsAndReservesBalanceNet	282226000
CY2021	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18632000
CY2021	amrn	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	128000
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2051000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	16709000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	20846000
CY2020	amrn	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	4608000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6822000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	18632000
CY2021	amrn	Contract With Customer Liability Revenue Recognized Excluding Performance Obligation Satisfied In Previous Period ContractWithCustomerLiabilityRevenueRecognizedExcludingPerformanceObligationSatisfiedInPreviousPeriod	1997000
CY2020	amrn	Contract With Customer Liability Revenue Recognized Excluding Performance Obligation Satisfied In Previous Period ContractWithCustomerLiabilityRevenueRecognizedExcludingPerformanceObligationSatisfiedInPreviousPeriod	4705000
CY2021	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	46000
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1262000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.115
CY2021	amrn	Operating Lease Change In Weighted Average Discount Rate Percent OperatingLeaseChangeInWeightedAverageDiscountRatePercent	0.01
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10300000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10600000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7700000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8100000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1600000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000

Files In Submission

Name	View Source	Status
0000950170-22-002401-index-headers.html	Edgar Link	pending
0000950170-22-002401-index.html	Edgar Link	pending
0000950170-22-002401.txt	Edgar Link	pending
0000950170-22-002401-xbrl.zip	Edgar Link	pending
amrn-20211231.htm	Edgar Link	pending
amrn-20211231.xsd	Edgar Link	pending
amrn-20211231_cal.xml	Edgar Link	unprocessable
amrn-20211231_def.xml	Edgar Link	unprocessable
amrn-20211231_htm.xml	Edgar Link	completed
amrn-20211231_lab.xml	Edgar Link	unprocessable
amrn-20211231_pre.xml	Edgar Link	unprocessable
amrn-ex10_35.htm	Edgar Link	pending
amrn-ex10_36.htm	Edgar Link	pending
amrn-ex10_37.htm	Edgar Link	pending
amrn-ex10_38.htm	Edgar Link	pending
amrn-ex10_54.htm	Edgar Link	pending
amrn-ex10_55.htm	Edgar Link	pending
amrn-ex10_56.htm	Edgar Link	pending
amrn-ex21_1.htm	Edgar Link	pending
amrn-ex23_1.htm	Edgar Link	pending
amrn-ex31_1.htm	Edgar Link	pending
amrn-ex31_2.htm	Edgar Link	pending
amrn-ex32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img14113915_0.jpg	Edgar Link	pending
img14113915_1.jpg	Edgar Link	pending
img14113915_2.jpg	Edgar Link	pending
img14113915_3.jpg	Edgar Link	pending
img15037436_0.jpg	Edgar Link	pending
img15037436_1.jpg	Edgar Link	pending
img15037436_2.jpg	Edgar Link	pending
img15037436_3.jpg	Edgar Link	pending
img150491009_0.jpg	Edgar Link	pending
img150491009_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRN
AMARIN CORP PLC\UK Stock $amrn

2021 Q4 Form 10-K Financial Statement

#000095017022002401 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN AMARIN CORP PLC\UK Stock $amrn

2021 Q4 Form 10-K Financial Statement

#000095017022002401 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN
AMARIN CORP PLC\UK Stock $amrn